Accuray TomoTherapy® Helical Radiotherapy System Helps Preserve Breast Cancer Patients’ Long-term Heart and Lung Functionality

SUNNYVALE, Calif.: SUNNYVALE, Calif., Feb. 10, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from a phase III, randomized controlled trial, TomoBreast, indicate post-surgery hypofractionated radiotherapy delivered with the TomoTherapy® System is superior to conventional radiotherapy in preserving long-term heart and lung functioning in women with early...

Click to view original post